NovaBay's CEO Featured in Insight Pharma Report

EMERYVILLE, Calif.--(BUSINESS WIRE)--Dr. Ron Najafi, Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (AMEX: NBY, www.novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, has been featured in the latest edition of Cambridge Healthtech Institute’s Insight Pharma Report.

In the article Dr. Najafi is interviewed by Dr. Leslie Pray of the Cambridge Healthtech Institute and highlights NVC-422, the Company’s lead non-antibiotic Aganocide® compound being developed to treat and prevent infections. Titled “Antibiotic R&D: Resolving the Paradox Between Unmet Medical Need and Commercial Incentive,” the article discusses NovaBay’s Aganocide compounds as they relate to the problem of antibiotic resistant infections.

“NovaBay is honored that the editors of the Insight Pharma Report took such an interest in our research and development of anti-infective compounds,” said Dr. Najafi. “The interview sheds light on how we are addressing the omnipresent staph infections and particularly the potentially deadly ‘superbug’ methicillin-resistant Staphylococcus aureus (MRSA) bacteria, an epidemic that, until recently, seems to have been largely unnoticed by the general public. MRSA is now responsible for more deaths than AIDS. Our two partnered industry leaders, Alcon and Kinetic Concepts, recognize the potential our compounds have in attacking a wide spectrum of infections.”

For an overview of the edition, please visit: http://www.insightpharmareports.com/reports_report.aspx?r=637&id=77482

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.

NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

NovaBay Pharmaceuticals, Inc.
Theresa Granados, 510-899-8870
Manager, Investor Relations
tgranados@novabaypharma.com
or
The Investor Relations Group
Investor Relations:
Adam Holdsworth / Erica Ruderman / Brett Foley
212-825-3210
or
Media Relations:
Janet Vasquez / Laura Colontrelle
212-825-3210